MedTrace Logo

Evaluation of a Program to Improve the Life Quality of Elderly

NCT06668740 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-12-03

No results posted yet for this study

Summary

Older people belong to an age group that has been increasing in recent decades, leading to a progressive ageing of the population. With the aim of reducing the generational digital divide, the use of technology in retirement homes was proposed. To this end, virtual reality glasses were used to allow the visualization of an external virtual world and, subsequently, it was evaluated whether their application improved the quality of life of the elderly by reducing the difficulties they have in participating in recreational activities outside these centers. A prospective quasi-experimental longitudinal study was carried out in the centers belonging to the basic health area of Valls, with a study period from May 2023 to March 2024. Quality of life was measured using the ad hoc "Escala de Calidad de Vida Rivas-Bordas".

Conditions

  • Elderly

Interventions

BEHAVIORAL

The use of Virtual Reality Glasses in Elderly

The group first completed a pretest, after which they watched 360-degree VR videos, such as nature walks and trips, for 10 minutes once a week over four weeks. Following this, a posttest was conducted. The outcomes will be used to measure changes in Quality of Life.

Sponsors & Collaborators

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2022-09-02
Completion
2024-04-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06668740 on ClinicalTrials.gov